Tuesday, May 17, 2005 12:17:23 AM
The conversation's about the deal between and CELG and ENMD, not CH (which also was years earlier).
ENMD had an active program for Thalidomide analogs at the time Thalidomide-for-cancer was sold to Celgene in the first place (Thalidomide analogs were specifically excluded from that deal). Those who enjoy "what-if" games can speculate over the potential outcomes of these: What if ENMD had put its resources behind Thalidomide (and not selling it out to CELG, who was in the leprosy business at that time), placed ES and AS on the back burner until the NCI came salavating over human trials, or got the pharmacokinetics right for PZ before going into the clinic in the first place?
But in all honesty, if I'd run the company at the time, I'd have wanted to swing at the ball pretty darned hard on every pitch. And anybody would still like to believe that the FDA wouldn't turn down a non-toxic cancer med...
But enough second guessing: Today's game is Panzem. I own season tickets (maybe a whole row or two in the section), I like the lineup, and I just cant wait to see the team in action.
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM